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Letter to the Editor (New Data) 
High mortality among older patients treated with pentavalent antimonials for visceral 
leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B 
 
Visceral leishmaniasis (VL; kala azar), a fatal disease if left untreated, is one of the most 
neglected tropical diseases. Poor and remote areas of South Asia and East Africa are the most 
affected. 
 
Pentavalent antimonial (SbV) drugs have been the mainstay of VL therapy in East Africa for 
the past 70 years. These drugs are administered parenterally for 30 days. Their potential for 
toxicity is high among VL patients, and drug-induced renal failure, acute pancreatitis, or 
cardiotoxicity can result in death. 
 
A growing body of clinical evidence shows that patients ≥45 years of age with leishmaniasis 
are at higher risk of death or severe adverse reactions during SbV treatment (1-6). Two 
separate studies conducted by Médecins Sans Frontières (MSF) in South Sudan showed that 
VL patients ≥45 years old treated with the SbV drug sodium stibogluconate (SSG) had 4.6 
(odds ratio [OR]; 95% CI: 2.7-7.7) (1) and 6.8 (relative risk [RR]; 95% CI: 4.4-10.4) (6) times 
higher risks of dying compared with younger patients (Table). 
 
More recent data analysis of MSF’s VL programs in Uganda and Ethiopia showed similar 
findings. In Uganda, where patients were primarily treated with either SSG or another SbV 
drug, meglumine antimoniate, age ≥45 years was the strongest independent risk factor for 
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mortality with an adjusted OR of 38.2 (95% CI: 11.8-123.2) (4). In Ethiopia, patients ≥45 
years old treated with SSG had 6.6 (OR; 95% CI: 3.2-13.9) higher risk of death compared to 
patients 5-29 years old (2). 
 
These risk ratios translated into case fatality rates (CFR) of 12% (2) to 30%, with three of the 
four studies demonstrating CFR 26-30% (Table) (1, 4, 6). 
 
This brief meta-analysis of MSF VL data shows that treatment with SbV of patients ≥45 years 
old results in unacceptably high mortality in East Africa. This may be caused by SbV toxicity, 
increased disease severity, or a combination of both. It is therefore urgent to evaluate 
potentially safer and more rapidly active treatments in this age group, such as liposomal 
amphotericin B (LAmB), miltefosine, or combination therapies (e.g. SbV with paromomycin 
for 17 days), and adapt national guidelines accordingly. 
 
LAmB (total dose 30 mg/kg) is now used by MSF in East Africa as compassionate treatment 
for patients ≥45 years old, and for other groups of patients at increased risk of complications 
or death due to SbV (e.g. HIV-TB co-infected, severely sick, or pregnant patients). Of 87 
patients ≥45 years old treated with LAmB by MSF in Sudan, Kenya, and Ethiopia since 2002, 
7 patients have died, giving a CFR of 8% (unpublished data). 
 
Despite recent drug price decreases, the cost of LAmB remains higher than SbV drugs, 
hindering its wider use. However, the incremental cost for increasing LAmB use would be 
expected to be relatively modest, since patients ≥45 years old represent a relatively small   3 
fraction (1.7-6.4%) of VL patients (Table). With a relatively small investment in LAmB, 
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Table. Summary of MSF studies examining age >45 years as a possible risk factor for death 
among VL patients treated with SbV in East Africa 
 
Study  Country 
Number of VL 
patients analyzed 
(>45 years old) 
Risk of death in 




Collin et al. 
2004 (1)  South Sudan  3,200 
(110) 
OR = 4.6 
[95% CI 2.7-7.7]
a  28.2% 
Seaman et al. 
1996 (6)  South Sudan  2,791 
(179) 
RR = 6.8 
[95% CI: 4.4-10.4]
b  26.3% 
Mueller et al. 
2009 (4)  Uganda  1,801 
(30) 
OR = 38.2 
[95% CI 11.8-123.2]
c  30.0% 
Herrero et al. 
2009 (2)  Ethiopia  2,177 
(106) 
OR = 6.6 
[95% CI 3.2-13.9]
d  12.3% 
 
a. Adjusted only for sex; comparator age group: 16-24 years 
b. Multivariable analysis; comparator age group: 5-14 years 
c. Multivariable analysis; comparator age group: 6-15 years 
d. Multivariable analysis; comparator age group: 5-29 years 
 
MSF, Médecins Sans Frontières; VL, visceral leishmaniasis; SbV, pentavalent antimonial; 
OR, odds ratio; RR, relative risk; CFR, case fatality rate 
 